GlobeImmune Selects Nextrials’ Prism to Manage Clinical Data in Upcoming Multi-site Oncology Trials

September 19, 2005

Applied Clinical Trials

Biopharmaceutical firm expands usage of Prism® to additional studies to facilitate real-time data capture and analysis

San Ramon, CA – September 19, 2005 – Nextrials, Inc., a leader in clinical research software and services, today announced that GlobeImmune, Inc. will expand the use of its flagship Prism® Electronic Data Capture (EDC) software to two upcoming clinical trials for a novel oncology therapeutic. GlobeImmune, a Denver-based biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, is currently using Prism to manage a clinical study for a treatment for chronic hepatitis C infection.

"For long-term studies conducted at multiple research sites, an EDC product such as Prism is invaluable for giving us an immediate snapshot of our progress," said John Ferraro, associate director of clinical operations for GlobeImmune. "Having theability to review data in real-time not only helps us better manage our clinical trials – it's absolutely essential for spotting potential adverse safety trends early to better safeguard our patients' health."

Prism pulls together formerly disparate clinical trials research activities such as project management, data management, product safety management, inventory control and related services into a comprehensive, web-enabled system. Data is collected,collapsed and centralized in real-time so that Prism's advanced data mining capability can deliver an accurate and timely picture of an ongoing study regardless of the number of test sites or enrolled patients involved. This increases theindustry's ability to conduct significant, complex clinical research in a safe and cost-effective environment.

"GlobeImmune is a company that is committed to using new technology that enhances patient safety through the improved delivery of information while reducing time to market," said James Rogers, co-founder and CEO of Nextrials. "Prism is provingthat, because it can give researchers immediate access to clinical data, it's changing the way that data can be used and analyzed. Researchers no longer have to wait days or weeks to identify trends or closely examine adverse effects. This helpspush new treatments to market more quickly, safely and cost-effectively."

About GlobeImmune, Inc.

Denver-based GlobeImmune, Inc., is an emerging biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. Thecompany's lead products are in Phase 1 testing for the treatment of hepatitis C infection and for the treatment of cancers of the lung and gastrointestinal tract. Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeastgenetically modified to express one or more protein antigens that stimulate the immune system against diseased cells. For additional information, please visit the company's website at www.globeimmune.com.

About Nextrials, Inc.

Founded by pharmaceutical researchers in 1999, Nextrials Innovates for Life™ by offering today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning ElectronicData Capture (EDC) solution, has been used at over 200 research sites to streamline the initiation and management of clinical trials.

The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.

Related Content:

News